HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Yao-Ping Lu Selected Research

Caffeine (No Doz)

1/2014PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis.
1/2013Mechanisms of Caffeine-Induced Inhibition of UVB Carcinogenesis.
1/2013Inhibition of UVB-induced nonmelanoma skin cancer: a path from tea to caffeine to exercise to decreased tissue fat.
8/2011Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.
7/2011Effects of high-fat diets rich in either omega-3 or omega-6 fatty acids on UVB-induced skin carcinogenesis in SKH-1 mice.
7/2011Caffeine decreases phospho-Chk1 (Ser317) and increases mitotic cells with cyclin B1 and caspase 3 in tumors from UVB-treated mice.
4/2008Effect of caffeine on the ATR/Chk1 pathway in the epidermis of UVB-irradiated mice.
3/2008Effect of caffeine on UVB-induced carcinogenesis, apoptosis, and the elimination of UVB-induced patches of p53 mutant epidermal cells in SKH-1 mice.
7/2007Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice.
1/2007Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Yao-Ping Lu Research Topics

Disease

15Neoplasms (Cancer)
03/2014 - 08/2002
9Skin Neoplasms (Skin Cancer)
01/2014 - 09/2002
7Sunburn
01/2014 - 01/2002
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2014 - 09/2002
2Keratoacanthoma
02/2014 - 06/2012
2Obesity
11/2011 - 10/2006
2Ataxia Telangiectasia (Louis Bar Syndrome)
08/2011 - 04/2008
2Hyperplasia
03/2008 - 08/2005
1Melanoma (Melanoma, Malignant)
01/2013
1Body Weight (Weight, Body)
11/2011
1Insulin Resistance
11/2011

Drug/Important Bio-Agent (IBA)

15Caffeine (No Doz)FDA LinkGeneric
01/2014 - 01/2002
6TeaIBA
01/2013 - 01/2002
5Caspase 3 (Caspase-3)IBA
06/2012 - 01/2002
2AdipokinesIBA
01/2013 - 06/2012
2CoffeeFDA Link
01/2013 - 07/2011
2DNA (Deoxyribonucleic Acid)IBA
01/2013 - 08/2011
2Cyclin B1IBA
07/2011 - 04/2008
2epigallocatechin gallate (epigallocatechin-3-gallate)IBA
09/2002 - 01/2002
1isothiocyanic acidIBA
03/2014
1sulforafan (sulforaphane)IBA
03/2014
1ParaffinIBA
02/2014
19-(2-hydroxy-3-nonyl)adenine (EHNA)IBA
01/2014
1Pyrimidine DimersIBA
01/2013
1salicylhydroxamic acid (SHAM)IBA
06/2012
1CytokinesIBA
06/2012
1Alanine Transaminase (SGPT)IBA
11/2011
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2011
1CholesterolIBA
11/2011
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
11/2011
1LipidsIBA
11/2011
1Blood Glucose (Blood Sugar)IBA
11/2011
1C-Reactive ProteinIBA
11/2011
1Phosphotransferases (Kinase)IBA
08/2011
1eucerinIBA
02/2009
1sodium benzoate drug combination caffeineIBA
03/2008
1ThymineIBA
01/2007
1Dietary Fats (Ghee)IBA
10/2006
1prolylleucineIBA
05/2005
1prolyl-serine (Pro-Ser)IBA
05/2005
1Codon (Codons)IBA
05/2005
1Green OrIBA
08/2002
1Bromodeoxyuridine (BrdU)IBA
01/2002

Therapy/Procedure

4Oral Administration
07/2011 - 01/2002
2Aftercare (After-Treatment)
08/2005 - 07/2004
1Lipectomy (Liposuction)
06/2012